{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T08:02:54Z","timestamp":1795161774023,"version":"4.10.3"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","award":["KitNewCare Project ID 101137054"],"award-info":[{"award-number":["KitNewCare Project ID 101137054"]}],"id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics","doi-asserted-by":"publisher","award":["PICKED Project ID 101168626"],"award-info":[{"award-number":["PICKED Project ID 101168626"]}],"id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","award":["COST Action PERMEDIK CA21165"],"award-info":[{"award-number":["COST Action PERMEDIK CA21165"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["CIFRA_COR-CM"],"award-info":[{"award-number":["CIFRA_COR-CM"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["P2022\/BMD-7223"],"award-info":[{"award-number":["P2022\/BMD-7223"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.diabres.2026.113496","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:17:44Z","timestamp":1786576664000},"page":"113496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibitor therapy in autosomal dominant polycystic kidney disease: systematic review and meta-analysis"],"prefix":"10.1016","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berk","family":"Mizrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdem","family":"Cig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4860-0594","authenticated-orcid":false,"given":"Enes","family":"Karakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-2486","authenticated-orcid":false,"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mallamaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Zoccali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.diabres.2026.113496_b0005","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1093\/ndt\/gfae240","article-title":"Inherited kidney disease and CAKUT are common causes of kidney failure requiring kidney replacement therapy: an ERA registry study","volume":"40","author":"Ortiz","year":"2025","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.diabres.2026.113496_b0010","doi-asserted-by":"crossref","unstructured":"KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int. 2025;107(2s):S1\u2013S239.","DOI":"10.1016\/j.kint.2024.07.009"},{"issue":"1","key":"10.1016\/j.diabres.2026.113496_b0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ndt\/gfaf159","article-title":"KDIGO 2025 ADPKD guideline: a commentary on diagnosis and management of hepatopancreatic manifestations by the ERA working group genes & kidney","volume":"41","author":"M\u00fcller","year":"2025","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"10.1016\/j.diabres.2026.113496_b0020","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.akdh.2024.07.003","article-title":"Autosomal dominant polycystic kidney disease","volume":"31","author":"Suarez","year":"2024","journal-title":"Adv Kidney Dis Health"},{"key":"10.1016\/j.diabres.2026.113496_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154937","article-title":"SGLT-2 inhibitors as cardio-renal protective agents","volume":"127","author":"Caruso","year":"2022","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.diabres.2026.113496_b0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.diabres.2026.113496_b0035","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113496_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.diabres.2026.113496_b0045","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1159\/000368540","article-title":"Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in Han: SPRD rats with polycystic kidney disease","volume":"40","author":"Rodriguez","year":"2015","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"10.1016\/j.diabres.2026.113496_b0050","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.diabres.2026.113496_b0055","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ckj\/sfac029","article-title":"Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction","volume":"15","author":"Afsar","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.diabres.2026.113496_b0060","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2026.113496_b0065","article-title":"Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease","volume":"17(8)","author":"Yoshimoto","year":"2024","journal-title":"Clin Kidney J"},{"issue":"7","key":"10.1016\/j.diabres.2026.113496_b0070","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.0000000725","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy and longitudinal changes in kidney function among veterans with autosomal dominant polycystic kidney disease","volume":"20","author":"Eswarappa","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.diabres.2026.113496_b0075","doi-asserted-by":"crossref","DOI":"10.1177\/20543581251404101","article-title":"Outcomes of patients with autosomal dominant polycystic kidney disease prescribed SGLT2 inhibitors in British Columbia: a single-arm retrospective cohort study","volume":"12","author":"Cau","year":"2025","journal-title":"Can J Kidney Health Dis"},{"issue":"4","key":"10.1016\/j.diabres.2026.113496_b0080","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.ekir.2025.01.023","article-title":"Open-label, randomized, controlled, crossover trial on the effect of dapagliflozin in patients with ADPKD receiving tolvaptan","volume":"10","author":"Uchiyama","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.diabres.2026.113496_b0085","article-title":"Dapagliflozin use in tolvaptan-treated patients with ADPKD: exploring renal outcomes in a retrospective study","volume":"18(9)","author":"Nakajima","year":"2025","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.diabres.2026.113496_b0090","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13730-025-00990-7","article-title":"Renoprotective effects of combination therapy with tolvaptan and dapagliflozin in autosomal dominant polycystic kidney disease: a four-case series","volume":"14","author":"Nishida","year":"2025","journal-title":"CEN Case Rep"},{"issue":"19","key":"10.1016\/j.diabres.2026.113496_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196341","article-title":"Short-term dapagliflozin administration in autosomal dominant polycystic kidney disease-a retrospective single-arm case series study","volume":"12","author":"Morioka","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2026.113496_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112357","article-title":"Impact of SGLT2 inhibitors on kidney health and survival in patients with polycystic kidney disease and type 2 diabetes","volume":"226","author":"Yen","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"37","key":"10.1016\/j.diabres.2026.113496_b0105","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2026.113496_b0110","doi-asserted-by":"crossref","unstructured":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4s):S117\u2013s314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"10.1016\/j.diabres.2026.113496_b0115","doi-asserted-by":"crossref","unstructured":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026, Diabetes Care, 2026;49(Supplement_1):S183\u2013s215.","DOI":"10.2337\/dc26-S009"},{"issue":"12","key":"10.1016\/j.diabres.2026.113496_b0120","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/ndt\/gfaf061","article-title":"SGLT2 inhibition for patients with ADPKD - closing the evidence gap","volume":"40","author":"Muller","year":"2025","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"10.1016\/j.diabres.2026.113496_b0125","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13730-023-00840-4","article-title":"Dapagliflozin administration for 1 year promoted kidney enlargement in patient with ADPKD","volume":"13","author":"Nakatani","year":"2024","journal-title":"CEN Case Rep"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272600416X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272600416X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:14:19Z","timestamp":1792804459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882272600416X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":25,"alternative-id":["S016882272600416X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113496","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibitor therapy in autosomal dominant polycystic kidney disease: systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113496","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113496"}}